NCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
Eli Lilly and Company
Takeda
CytomX Therapeutics
AstraZeneca
Takeda
Takeda
Hoffmann-La Roche
Eisai Inc.
Xencor, Inc.
EMD Serono
AstraZeneca
Cyclacel Pharmaceuticals, Inc.
Hoffmann-La Roche
Lumos Pharma
Centro Nacional de Investigaciones Oncologicas CARLOS III
Incyte Corporation
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Debiopharm International SA
GC Biopharma Corp
EMD Serono
SCRI Development Innovations, LLC
AstraZeneca
Dana-Farber Cancer Institute